POPULARITY
4 episodes with Recombinant
4 episodes with Recombinant
3 episodes with Recombinant
2 episodes with Recombinant
6 episodes with Recombinant
2 episodes with Recombinant
2 episodes with Recombinant
2 episodes with Recombinant
2 episodes with Recombinant
In this special episode of Diabetes Core Update, our host, Dr. Neil Skolnik, discusses with two expert guests the recommendations for respiratory vaccinations in people with diabetes, the rise in vaccine hesitancy and some of the possible reasons for this hesitancy, and several ways to address vaccine hesitancy in the office. This special edition is sponsored by Sanofi. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington–Jefferson Health John J. Russell, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair, Department of Family Medicine, Abington–Jefferson Health Aaron Sutton, LCSW, BCD, CAADC, Behavioral Health Faculty at the Family Medicine Residency Program at Abington–Jefferson Health; Chief Wellness Officer for Graduate Medical Education at Abington–Jefferson Health Select references mentioned in the podcast: Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024–25 Influenza Season. MMWR Recomm Rep 2024;73:1–25. DOI: 10.15585/mmwr.rr7305a1 Recombinant or Standard-Dose Influenza Vaccine in Adults Under 65 Years of Age. N Engl J Med 2023;389:2245–2255. DOI: 10.1056/NEJMoa2302099 Influenza Vaccine as a Coronary Intervention for Prevention of Myocardial Infarction. Heart 2016;102:1953–1956. DOI: 10.1136/heartjnl-2016-309983
Send us a textWandering around Chicago in 1912 William Klann was a man on a mission. He was part of a team set up to explore ways in which they could reduce the costs of manufacturing a car to fulfil Henry Ford's vision of ‘a motor car for the great multitude'. They had already developed many of the ideas behind mass production — standardized and interchangeable parts, short task cycle work, specialist machinery — but what Klann saw while walking past the Swift Meat Packing Company's factory gave him an insight into a key piece of the puzzle.The workers were effectively disassembling meat carcasses, stripping off various joints and cuts as the animals were led past them on a moving overhead conveyor. In a classic moment of insight, he saw the possibility of reversing this process — and within a short space of time, the Ford factory boasted the world's first moving assembly line. Productivity rocketed as the new idea was implemented and refined; using the new approach Ford was able to cut the assembly time for a Model T to just 93 minutes.60 years later, and in another part of the world, Dr Govindappa Venkataswamy retired. He'd worked for many years as Head of Opthalmology in the main hospital in Madurai, India, and decided to use his expertise and new-found free time to try and help prevent blindness in rural communities in his home state of Tamil Nadu. This was not an insignificant problem — whilst the treatment itself is well-developed it comes at a price; in an Indian hospital, the cost works out to around $300, and in a country where most people, especially in rural environments, earn less than $2/day such a price tag puts treatment out of reach.In order to achieve his dream he had to search outside the conventional health sector, seeking ideas from other worlds with similar challenges. Specifically, he looked for low-cost ways of carrying out activities systematically, reproducibly, and to a high-quality standard — and eventually found inspiration in McDonald's. He saw the underlying similarities in the core processes they used and adapted their principles of assembly line manufacturing to the context of eye surgery!Developing and refining what became known as the Aravind system has meant that the average cost of a cataract operation is now $25, and over 60% of patients are treated for free. This isn't done by compromising on quality — Aravind has better performance than many Western hospitals. It has become the world's largest and most productive eye-care service group, responsible for treating over 35 million patients with its low-cost/high-quality model.What these stories have in common is that they are working on the same problem, just in a different context. This is a powerful resource in innovation — answers don't always have to be new to the world, they can also be adapted from different contexts. Recombinant innovation.It's not a new idea. Thomas Edison was an early and active exponent, seeing the possibilities in drawing on many examples of proven technology and reapplying them in different fields. His ‘invention factory' in New Jersey offered the world ‘…a minor invention every ten days, and a big one every six months or so….' and it largely succeeded.This podcast explores the theme of recombinant innovation and some strategies to help develop it as a key innovation capabilityIf you'd like to explore more innovation stories, or access a wide range of resources to help work with innovation, then please visit my website here.You can find a rich variety of cases, tools, videos, activities and other resources - as well as my innovation blog.Or subscribe to my YouTube channel here
MedLink Neurology Podcast is delighted to feature selected episodes from BrainWaves, courtesy of James E Siegler MD, its originator and host. BrainWaves is an academic audio podcast whose mission is to educate medical providers through clinical cases and topical reviews in neurology, medicine, and the humanities. Episodes originally aired from 2016 to 2021.Originally released: October 17, 2019College is a tough time for any kid. But it should also be exciting. Then to experience the freedoms of young adulthood, only later to face the horrifying reality of a progressive neurodegenerative condition...it's not something anyone should experience. In this week's continuation of the patient narrative series, Dr. Paul McIntosh (Duke) shares his life-changing story and his optimism about surviving a chronic neurologic illness.Produced by James E Siegler with the help of Paul McIntosh. For more information about Pompe Disease, check out the resources provided by the United Pompe Foundation at unitedpompe.com. Music for our program this week was courtesy of Ars Sonor, Franz Danzi, Lee Rosevere, and Scott Holmes. Sound effects by Mike Koenig and Daniel Simion. BrainWaves' podcasts and online content are intended for medical education only and should not be used for clinical decision-making. Be sure to follow us on Twitter (now X) @brainwavesaudio for the latest updates to the podcast.REFERENCESBeltran Papsdorf TB, Howard JF Jr, Chahin N. Pearls & Oy-sters: clues to the diagnosis of adult-onset acid maltase deficiency. Neurology 2014;82(9):e73-5. PMID 24590251Cupler EJ, Berger KI, Leshner RT, et al. Consensus treatment recommendations for late-onset Pompe disease. Muscle Nerve 2012;45(3):319-33. PMID 22173792Gutiérrez-Rivas E, Bautista J, Vílchez JJ, et al. Targeted screening for the detection of Pompe disease in patients with unclassified limb-girdle muscular dystrophy or asymptomatic hyperCKemia using dried blood: a Spanish cohort. Neuromuscul Disord 2015;25(7):548-53. PMID 25998610Kishnani PS, Howell RR. Pompe disease in infants and children. J Pediatr 2004;144(5 Suppl):S35-43. PMID 15126982Kishnani PS, Corzo D, Nicolino M, et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 2007;68(2):99-109. PMID 17151339Klinge L, Straub V, Neudorf U, et al. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial. Neuromuscul Disord 2005;15(1):24-31. PMID 15639117Lukacs Z, Nieves Cobos P, Wenninger S, et al. Prevalence of Pompe disease in 3,076 patients with hyperCKemia and limb-girdle muscular weakness. Neurology 2016;87(3):295-8. PMID 27170567Van den Hout JM, Kamphoven JH, Winkel LP, et al. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 2004;113(5):e448-57. PMID 15121988van der Ploeg AT, Clemens PR, Corzo D, et al. A randomized study of alglucosidase alfa in late-onset Pompe's disease. N Engl J Med 2010;362(15):1396-406. PMID 20393176Wokke JH, Escolar DM, Pestronk A, et al. Clinical features of late-onset Pompe disease: a prospective cohort study. Muscle Nerve 2008;38(4):1236-45. PMID 18816591We believe that
In this episode, we review the high-yield topic of Recombinant Cytokines from the Rheumatology section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets Linkedin: https://www.linkedin.com/company/medbullets
Monsanto has been voted "The Most Evil Company In The World" multiple times. But, who are they? Who runs and financially backs them? What do they do and most importantly... where did they go? You need to know this information! It affects every aspect of your life!Email us at: downtherh@protonmail.comThis show is part of the Spreaker Prime Network, if you are interested in advertising on this podcast, contact us at https://www.spreaker.com/show/4656375/advertisement
Check out our free downloads at nascentmc.com: Implementing AMA Style – 8 Things to Get Right in Your Next Project Needs Assessments – 7 Essentials for Getting Funded Working With Your Medical Writer – 8 Ways to Get the Most out of Them See the full write ups for today's episode at nascentmc.com/podcast Here are the highlights: The FDA has approved Zepbound (tirzepatide) for adults with obesity, allowing its use in individuals with a body mass index (BMI) of 30 or more, as well as overweight individuals (BMI of 27 or greater) with at least one weight-related condition. Tirzepatide, an agonist of GLP-1 and GIP, was shown to significantly reduce body weight when used in combination with a reduced-calorie diet and increased physical activity in clinical trials, but it may have adverse effects, including gastrointestinal issues and a potential link to medullary thyroid cancer. Ixchiq has become the first FDA-approved chikungunya vaccine for individuals aged 18 and older at increased risk of exposure to the chikungunya virus, which is primarily transmitted by mosquitoes. Chikungunya is a global health threat with symptoms including fever, joint pain, and rash, and severe joint pain that can last for months. The vaccine, while effective, may cause severe or prolonged chikungunya-like adverse reactions, and the manufacturer, Valneva, is required to conduct a postmarketing study to assess these risks. Fruzaqla (fruquintinib) has received FDA approval for patients with metastatic colorectal cancer (mCRC) who have undergone previous treatments, including various chemotherapy and targeted therapies. Fruquintinib, a kinase inhibitor of VEGFRs, demonstrated improvements in overall survival and progression-free survival in clinical trials, with consistent safety profiles. The approval was granted to Takeda, and the drug is also under review for marketing authorization in Europe. Adzynma (ADAMTS13, recombinant-krhn) has been approved by the FDA for congenital thrombotic thrombocytopenic purpura (cTTP), making it the first FDA-approved recombinant ADAMTS13 protein for this rare condition. cTTP results from a deficiency in ADAMTS13, leading to blood clot formation and severe bleeding episodes. Adzynma serves as prophylactic and on-demand treatment, with promising results in a phase 3 study, and its approval was granted to Takeda. Intro and outro music Garden Of Love by Pk jazz Collective
Dr. Rothman interviews Drs. Stratton and Yang to discuss the treatment landscape of Duchenne Muscular Dystrophy, highlighting Elevidys, the newly approved recombinant gene therapy.
Dr Keith Chappell discusses the bivalent recombinant vaccine for COVID-19 following the study by Dayan and colleagues, with focus on vaccine access, variants and boosters, tolerability and side effects, as well as hopes for future trials.Continue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
Vincent speaks with Raul and Kostya about the development of novel oral polio vaccine from the Sabin type 2 strain, its deployment in over 600 million children, and whether it can lead to eradication of poliomyelitis. Host: Vincent Racaniello Guests: Raul Andino and Kostya Chumakov Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode MicrobeTV Discord Server MicrobeTV store at Cafepress Research assistant position in Rosenfeld Lab CBER/FDA (pdf) Engineering OPV (Cell Host Microbe) Poliopolis (Lancet) nOPV2 (Polioeradication.org) Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv
Dr. Björn Mellgård, VP and Global Program Lead of rare genetics and hematology at Takeda, is passionate about finding a cure for cTTP, congenital thrombotic thrombocytopenic purpura. This ultra-rare disease, caused by an enzyme deficiency, presents in early childhood and results in life-threatening blood clots. With their investigational drug TAK-755, a recombinant enzyme, the volume is very small, and the infusion takes four to five minutes and is a replacement therapy to allow patients to avoid daily symptoms and acute episodes. Björn explains, "What happens then is that we have our coagulation system, and many people have heard about bleeding disorders, mainly probably hemophilia, where you lack certain factors which are important to make the blood clot. TTP is on the other side of the spectrum, and the deficiency we're talking about, this ADAMTS13 enzyme, is also importantly involved in blood coagulation." "But the effect is when you don't have this enzyme present. The blood has a tendency to spontaneously form blood clots in the circulation. And these blood clots then tend to lodge in critical organs such as the brain, the heart, and the kidney, and the patients then suffer symptoms based on that." "So, our drug then represents a recombinant enzyme. So, it's a recombinant protein that is produced in a laboratory. It's exactly the same as we have in our bodies. And this kind of replacement therapy has been used for a long time. And I mentioned hemophilia as an example where Takeda and also other companies have recombinant factor VIII in that case. So, the principle behind this treatment is to give the patient what they're missing. That's pretty straightforward in some sense." #Takeda #cTTP #TAK755 #RecombinantEnzyme #RareDisease Takeda.com Download the transcript here
Dr. Björn Mellgård, VP and Global Program Lead of rare genetics and hematology at Takeda, is passionate about finding a cure for cTTP, congenital thrombotic thrombocytopenic purpura. This ultra-rare disease, caused by an enzyme deficiency, presents in early childhood and results in life-threatening blood clots. With their investigational drug TAK-755, a recombinant enzyme, the volume is very small, and the infusion takes four to five minutes and is a replacement therapy to allow patients to avoid daily symptoms and acute episodes. Björn explains, "What happens then is that we have our coagulation system, and many people have heard about bleeding disorders, mainly probably hemophilia, where you lack certain factors which are important to make the blood clot. TTP is on the other side of the spectrum, and the deficiency we're talking about, this ADAMTS13 enzyme, is also importantly involved in blood coagulation." "But the effect is when you don't have this enzyme present. The blood has a tendency to spontaneously form blood clots in the circulation. And these blood clots then tend to lodge in critical organs such as the brain, the heart, and the kidney, and the patients then suffer symptoms based on that." "So, our drug then represents a recombinant enzyme. So, it's a recombinant protein that is produced in a laboratory. It's exactly the same as we have in our bodies. And this kind of replacement therapy has been used for a long time. And I mentioned hemophilia as an example where Takeda and also other companies have recombinant factor VIII in that case. So, the principle behind this treatment is to give the patient what they're missing. That's pretty straightforward in some sense." #Takeda #cTTP #TAK755 #RecombinantEnzyme #RareDisease Takeda.com Listen to the podcast here
Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.06.28.546392v1?rss=1 Authors: Mitchell, K. G., Gong, B., Hunter, S. S., Burkart-Waco, D., Gavira-ONeill, C. E., Templeton, K. M., Goethel, M. E., Bzymek, M., MacNiven, L. M., Murray, K. D., Settles, M. L., Froenicke, L., Trimmer, J. S. Abstract: The Neuroscience Monoclonal Antibody Sequencing Initiative (NeuroMabSeq) is a concerted effort to determine and make publicly available hybridoma-derived sequences of monoclonal antibodies (mAbs) valuable to neuroscience research. Over 30 years of research and development efforts including those at the UC Davis/NIH NeuroMab Facility have resulted in the generation of a large collection of mouse mAbs validated for neuroscience research. To enhance dissemination and increase the utility of this valuable resource, we applied a high-throughput DNA sequencing approach to determine immunoglobulin heavy and light chain variable domain sequences from source hybridoma cells. The resultant set of sequences was made publicly available as searchable DNA sequence database (neuromabseq.ucdavis.edu) for sharing, analysis and use in downstream applications. We enhanced the utility, transparency, and reproducibility of the existing mAb collection by using these sequences to develop recombinant mAbs. This enabled their subsequent engineering into alternate forms with distinct utility, including alternate modes of detection in multiplexed labeling, and as miniaturized single chain variable fragments or scFvs. The NeuroMabSeq website and database and the corresponding recombinant antibody collection together serve as a public DNA sequence repository of mouse mAb heavy and light chain variable domain sequences and as an open resource for enhancing dissemination and utility of this valuable collection of validated mAbs. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC
In one sentence...Aging is malleable and there is a particular, mysterious protein of interest that may enable new therapies for age-related diseases such as stroke, diabetes, and obesity.Young blood in old bodies has been demonstrated in several studies to counteract some age-correlated ailments. Mark Allen, a medical doctor by training and an entrepreneur in practice, co-founded Elevian to understand and commercialize therapies using a recombinant growth differentiation factor known as GDF11, a ‘magic' protein, as referenced by the New York Times. Dr. Allen describes how his team is developing new medicines targeting the aging process, rather than the prevailing approach of most pharmaceutical products that target individual diseases. Highlighting a surprising result, if humanity was able to eradicate cancer completely, the outcome would only increase the average human lifespan by an estimated two to three years, while doubling the incidence of age-related diseases such as Alzheimer's. With its scientific foundations beginning emerging from the Harvard Stem Cell Institute, the Elevian team is rigorously exploring GDF11 and its effective use while navigating commercialization challenges. Specifically, how can an age-related therapy be reimbursable when “age” is not yet officially a disease (based on medical billing code)? We discuss with Dr. Allen about Elevian's path ahead and the strategies at work.
Gaining trust is important, both in our daily lives and in the laboratory. But how do we build trust in science? In our research? Join us as we delve into the world of scientific reproducibility and explore how common laboratory tools may be hindering progress. Professor Pierre Cosson shares his expert insights with Joshua on the state of science today and reveals how the development of recombinant antibodies could be the game-changer we've all been waiting for. If you're ready to be on the cutting-edge of scientific discovery and learn how to build trust in your research, then don't miss out on this episode of Biosounds! Introduction by Davide D'Amico.
Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.03.03.530962v1?rss=1 Authors: Noes-Holt, G., Jensen, K. L., Richner, M., Baro, R. C., Sivertsen, L., Jager, S. E., Fernandez, L. J., Andersen, R. C., Lilja, J. H., Larsen, A. H., Christiansen, N. R., Tappe-Theodor, A. E., Vaegter, C. B., Kuner, R., Madsen, K. L., Soerensen, A. T. Abstract: Chronic pain is estimated to affect 20% of the adult population, and the burden on individual patients and society caused by chronic pain is escalating. Current treatments, including opioids, anti-convulsants, and anti-depressants, are only moderately effective and limited by severe side effects and addiction liability. The inadequate state of current treatment, the chronic nature of particularly neuropathic pain, and the high impact on quality of life render chronic pain conditions relevant for gene therapy. Here, we describe the development of a self-assembling, bivalent peptide inhibitor of the pain-associated scaffold protein PICK1, delivered by adeno-associated viral (AAV) vectors. This strategy prevents mechanical allodynia in mouse inflammatory and neuropathic pain models and reverses neuropathic pain in advanced stages for an entire year. Pain relief was obtained by selective targeting of several relays along the somatosensory pain pathways without observed side effects. Importantly, full pain relief was also achieved by selective transduction of peripheral neurons, which is highly attractive for therapeutic intervention since it is less likely to cause intolerable side effects. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC
Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.02.13.528249v1?rss=1 Authors: Jing, J., Chen, S., Wu, X., Yang, J., Liu, X., Wang, J., Wang, J., Li, Y., Zhang, P., Tang, Z. Abstract: Intracerebral hemorrhage (ICH) is an acute cerebrovascular disease with high disability and mortality rates. Recombinant tissue plasminogen activator (rtPA) is commonly applied for hematoma evacuation in minimally invasive surgery (MIS) after ICH. However, rtPA may contact directly with brain tissue during MIS procedure, which makes it necessary to discuss the safety of rtPA. We found that, in the in vivo ICH model induced by VII-type collagenase, rtPA treatment improved the neurological function of ICH mice, alleviated the pathological damage and decreased the apoptosis and autophagy level of the peri-hematoma tissue. In the in-vitro model of ICH induced by hemin, the administration of rtPA down-regulated neuronal apoptosis, autophagy, and endoplasmic reticulum stress of neurons. Transcriptome sequencing analysis showed that rtPA treatment upregulated the PI3K/AKT/mTOR pathway in neurons, and PI3K inhibitor (LY294002) can reverse the protective effects of rtPA in inhibiting excessive apoptosis, autophagy and ER-stress. Epidermal growth factor receptor inhibitor (AG-1487) reversed the effect of rtPA on PI3K/AKT/mTOR pathway, which might indicate that the EGF domain played an important role in the activation of PI3K/AKT/mTOR pathway. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC
Savez-vous comment sont réalisés les tests endotoxines ? Et bien dans cette interview de Yohann CAHON de la société Cape Code Associates vous allez le découvrir est bien plus encore ! Yohann nous parle des réactifs recombinants, une nouvelle technologie qui qui vise à remplacer le LAL (Limulus amebocyte lysate) pour se passer des limules, ces animaux préhistoriques dont le sang contient les précieuses enzymes nécessaire pour réaliser ces fameux tests !
Do you know how endotoxin tests are carried out? Well, in this interview with David Guy from Cape Code Associates, you'll find out ! David tells us about recombinant reagents, a new technology that aims to replace LAL (Limulus amebocyte lysate) and stop using horseshoe crabs, these prehistoric animals whose blood contains the precious enzymes necessary to perform these famous tests!
FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)
Listen to a soundcast of the November 18, 2022 FDA approval of a new dosing regimen for asparaginase erwinia chrysanthemi (recombinant).
Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2022.12.22.521561v1?rss=1 Authors: Niwa, S., Chiba, K. Abstract: Kinesin-1, a motor protein composed of the kinesin heavy chain (KHC) and the kinesin light chain (KLC), is fundamental to cellular morphogenesis and function. A monoclonal antibody (mAb) called H2 recognizes the KHC in a broad range of species and is one of the most widely used mAbs in cytoskeletal motor research. Here, we generated vectors that expressed recombinant H2 in mammalian cells. We demonstrated that the recombinant H2 performed as well as the hybridoma-derived H2 in western blotting and immunofluorescence assays. The recombinant H2 could detect all three human KHC isotypes (KIF5A, KIF5B, and KIF5C) and amyotrophic lateral sclerosis (ALS)-associated KIF5A aggregates in the cell. Immunofluorescence microscopy showed that the single chain variable fragment (scFv) derived from the H2 mAb could specifically recognize KHCs in cells. In addition, we developed a chickenized anti-KHC scFv(H2), which broadens the application of H2 in immunofluorescence microscopy. Collectively, our findings validate recombinant H2 as useful for studying the function of KHCs. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC
Safe Jabs Thanks to Horseshoe Crabs: Making Sure Your Injection is Free of Endotoxins Allen Burgenson, Lonza's expert for all things testing, speaks to us about the dangers of endotoxin contamination and the future of non-animal testing for it. “Before testing for endotoxins in the 1940s, a physician literally had to gauge the risk to your life because of something called injection fever,” explains Allen Burgenson. Luckily, we've come a long way since then. Thanks to advanced testing methods, one can rest assured today that any sort of injection or implant is completely free of dangerous endotoxins. Currently, the predominant mode is Limulus Amebocyte Lysate (LAL) testing, in which scientists harvest the bright blue blood of American Horseshoe Crabs and use the animal's primitive immune system to look for clotting reactions that would indicate the presence of any endotoxins. The horseshoe crabs, Burgenson explains, survive the extraction unscathed and are safely returned to the waters in less than 24 hours. However, in a continual attempt to remove animals from the testing pipeline, Lonza's recombinant factor C assay known as PyroGene could eventually replace LAL testing.
These flu shots are better for animals and just as effective, researchers say by Karen Asp at SentientMedia.org. Original post: https://sentientmedia.org/effective-flu-shots-that-spare-animals/ Sentient Media is a nonprofit news organization that is changing the conversation around animal agriculture across the globe. They seek to create and sustain a sense of global urgency about the agriculture industry's impact on the climate crisis, extraction of natural resources and systematic exploitation of the fringes of society. They're doing this through critical commentary, investigative journalism, creating resources, strengthening the journalist and advocate community, partnering with publishers and holding the media accountable when it fails to report on the most pressing issues of our time. As a non-profit, Sentient Media relies on its readers and generous donors to continue their work. How to support the podcast: Share with others. Recommend the podcast on your social media. Follow/subscribe to the show wherever you listen. Buy some vegan/plant based merch: https://www.plantbasedbriefing.com/shop Follow Plant Based Briefing on social media: Twitter: @PlantBasedBrief YouTube: YouTube.com/PlantBasedBriefing Facebook: Facebook.com/PlantBasedBriefing LinkedIn: Plant Based Briefing Podcast Instagram: @PlantBasedBriefing #vegan #plantbased #veganpodcast #plantbasedpodcast #plantbasedbriefing #sentientmedia #newsorganization #flu #flushot #fluvaccine #cdc #influenza #eggs #chickens #eggfree #cellbasedflushot #recombinant #recombinantvaccine #eggfreeflushot #eggfreefluvaccine
Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2022.11.24.517538v1?rss=1 Authors: Sampedro-Castaneda, M., Baltussen, L. L., Lopes, A. T., Qiu, Y., Sirvio, L., Mihaylov, S. R., Claxton, S., Richardson, J. C., Lignani, G., Ultanir, S. K. Abstract: Developmental and epileptic encephalopathies (DEEs) are a group of rare childhood disorders characterized by severe epilepsy and related cognitive deficits. Numerous DEE genes have been discovered thanks to advances in genomic diagnosis, yet putative molecular links between these disorders are not known. CDKL5 deficiency disorder (CDD, DEE2) is one of the most common forms of genetic epilepsy; it is caused by loss-of-function mutations in the brain-enriched kinase CDKL5. To elucidate CDKL5 function, we looked for CDKL5 substrates using a SILAC based phosphoproteomic screen. We identified the voltage-gated Ca2+ channel Cav2.3 (encoded by CACNA1E) as a novel physiological target of CDKL5 in mice and humans. Recombinant channel electrophysiology and interdisciplinary characterization of Cav2.3 phosphomutant mice revealed that the loss of Cav2.3 phosphorylation leads to channel gain-of-function via slower channel inactivation and enhanced acetylcholine-induced stimulation, resulting in increased neuronal excitability. These changes in Cav2.3 closely resemble those described for gain-of-function point-mutations in CACNA1E that cause DEE69, a disorder sharing clinical features with CDD. Our results show that these two single-gene disorders are mechanistically related. We suggest that CDD is partly a channelopathy with Cav2.3 gain-of-function, thus Cav2.3 inhibition could be therapeutic in these DEEs. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC
In this episode, we discuss the fundamentals and approaches to chronic management and treatment for patients with known inherited hemophilia. What is hemophilia?* As name suggests, tendency to bleed* Two types: genetic and acquiredInherited hemophilia: * Genetic: sex-linked, meaning males will express it, females will, by and large be carriers * Main ones to be worried about: Hemophilia A and Hemophilia B** Hemophilia A: deficiency in factor VIII (1:5000 men)** Hemophilia B: deficiency in factor IX (1:30,000 men)** Thousands of underlying mutations * We grade the severity of hemophilia using the factor activity levels: ** Severe: 1 bleed into the joints for patients with severe hemophilia (goal is to keep levels >1%)** In patients with moderate or mild can do intermittent dosing *Hemophilia A/Factor VIII replacement (many options; here is what we use at Rouleaux): **Recombinant factor concentrates: Advate**Plasma-derived concentrates: Humate-P* Factor IX replacement: ** Recombinant factor concentrates: BenefIX*Bypassing agents: For patients with inhibitors (to be discussed in a future episode) or can be used for Hemophilia A or B*Options:** Novoseven (activated recombinant factor VII): Activates the extrinsic pathway to bypass the need for factors VIII or IX** FEIBA (factor eight inhibitor bypassing agent): Activated prothrombin complex concentrate (FIIa, VIIa, Xa)* Emicizumab (Hemlibra): bispecific monoclonal antibody that binds factor activated IX and X → essentially doing the job of factor VIII and leads to activation of the downstream common pathway** Note that it binds activated factor IX not inactivated factor IX and this is why you won't just constantly form clots by forcing down the common pathway like you would by giving a bypassing agent***cannot be used in Hemophilia B because it relies on the presence of factor IX**** Several new therapies have been introduced in recent yearsReferences:https://www.uptodate.com/contents/hemophilia-a-and-b-routine-management-including-prophylaxis?search=hemophilia%20treatment&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2: UpToDate article on current management of Hemophilia DOI: 10.1055/s-0042-1756188: “The More Recent History of Hemophilia Treatment.” Semin Thromb Hemost. 2022. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast
Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2022.11.10.516027v1?rss=1 Authors: Asteriti, S., Marino, V., Avesani, A., Biasi, A., Dal Cortivo, G., Cangiano, L., Dell'Orco, D. Abstract: Retinal dystrophies of genetic origin are often associated with mutations in the genes involved in the phototransduction cascade in photoreceptors, a paradigmatic signaling pathway mediated by G protein-coupled receptors. Photoreceptor viability is strictly dependent on the levels of the second messengers cGMP and Ca2+. Here we explored the possibility of modulating the phototransduction cascade in mouse rods using direct or liposome-mediated administration of a recombinant protein crucial for regulating the interplay of the second messengers in photoreceptor outer segments. The effects of administration of the free and liposome-encapsulated human guanylate cyclase-activating protein (GCAP1) were compared in biological systems of increasing complexity (in cyto, ex vivo, and in vivo). Analysis of protein biodistribution and direct measurement of functional alteration in rod photoresponses show that the exogenous GCAP1 protein is fully incorporated into the mouse retina and photoreceptor outer segments. Furthermore, only in the presence of a point mutation associated with cone-rod dystrophy in humans p.(E111V), protein delivery induces a disease-like electrophysiological phenotype, consistent with constitutive activation of the retinal guanylate cyclase. Our study demonstrates that both direct and liposome-mediated protein delivery are powerful tools for targeting signaling cascades in neuronal cells, which could be particularly important for the treatment of autosomal dominant genetic diseases. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC
An RSV vaccine, if approved, may reduce disease burden in older adults. In this recap of the most common questions from a symposium at the Family Medicine Experience 2022 conference, listen as we discuss when an RSV vaccine may be approved and how to overcome barriers to the implementation of vaccines for older adults in primary care settings.Hear answer to questions such as:When might potential RSV vaccines be available, and when might the Advisory Committee on Immunization Practices make recommendations on their use?How will the vaccine roll out? Who would receive the vaccine first?If approved, what will the RSV vaccination schedule be?How can we overcome vaccine hesitancy?PresentersJohn J. Russell, MD, FAAFPClinical Professor of Family and Community MedicineSidney Kimmel College of MedicineThomas Jefferson UniversityPhiladelphia, PennsylvaniaChair, Department of Family and Community MedicineAbington-Jefferson HealthAbington, PennsylvaniaLaura Hurley, MD, MPHAssociate Professor of MedicineDivision of General Internal MedicineDepartment of MedicineUniversity of Colorado Anschutz Medical CampusAurora, ColoradoPrimary Care PhysicianDivision of General Internal MedicineDepartment of MedicineDenver HealthDenver, ColoradoPamela Rockwell, DO, FAAFPProfessorFamily MedicineUniversity of Michigan Medical SchoolAnn Arbor, MichiganView the full program at:https://bit.ly/3Wt87GI
In Part 2 of our Hemophilia B episode, we spotlight research priorities into women with hemophilia B, novel therapies to treat people with hemophilia B, and we conclude the story of Alexei Nikolaevich, the last Tsesarevich of Russia. Contributors: Bethany Samuelson Bannow, MD Brian O'Mahony Kathaleen M. Schnur, MSW, LCSW Senior Advisor: Donna DiMichele, MD Episode Advisors (also contributors): Dr. Amy Shapiro Professor Jan Astermark Hosted by: Laurence Woollard Links to learn more: Brown A. "The Royal Disease and The Royal Collapse: Political Effects of Hemophilia in the Royal Houses of Europe." Honor Scholar Theses. 2017;63. [Online]. Available at: https://scholarship.depauw.edu/cgi/viewcontent.cgi?article=1063&context=studentresearch [Accessed 10 October 2022] Gualtierotti R, et al. Updates on novel non-replacement drugs for hemophilia. Pharmaceuticals 2022;15(10):1183. Doi: 10.3390/ph15101183 Hart DP, et al. International consensus recommendations on the management of people living with haemophilia B. Ther Adv Hematol 2022;13:1-22. Doi: 20406207221085202 Hoffman TA. "Bad Blood: Hemophilia and Its Detriment to the Russian Imperial Family." Young Historians Conference. 2022;8. [Online]. Available at: https://pdxscholar.library.pdx.edu/cgi/viewcontent.cgi?article=1244&context=younghistorians [Accessed 10 October 2022] Lannoy N, Hermans C. The ‘royal disease' – haemophilia A or B? A haematological mystery is finally solved. Haemophilia 2010;16:843-47. Doi: 10.1111/j.1365-2516.2010.02327.x Nathwani A, et al. Liver gene therapy. Hum Gene Thur 2022;33:17-18. Doi: 10.1089/hum.2022.169 O'Donovan M, et al. Recombinant factor IX-Fc fusion protein in severe hemophilia B: Patient-reported outcomes and health-related quality of life. Res Pract Thromb Haemost 2021;5(7):e12602. Doi: 10.1002/rth2.12602 Peeling S. Russo-Japanese War. International Encyclopaedia of the First World War. 1914-1918. [Online]. Available at: https://encyclopedia.1914-1918-online.net/article/russo-japanese_war [Accessed 10 October 2022] Potts WTW. Royal haemophilia. J Biol Educ 1996;30(3):207-17. DOI: 10.1080/00219266.1996.9655504 Price KD. "Diary of Nicholas II, 1917-1918, an annotated translation." Graduate Student Theses, Dissertations, & Professional Papers. 1966;2065. [Online]. Available at: https://scholarworks.umt.edu/cgi/viewcontent.cgi?article=3084&context=etd [Accessed 10 October 2022] Radcliffe J. “Rasputin and the Fragmentation of Imperial Russia.” Young Historians Conference. 2017;14. [Online]. Available at: https://pdxscholar.library.pdx.edu/younghistorians/2017/oralpres/14/ [Accessed 10 October 2022] Show Notes: Presenting Sponsor: Sanofi Subscribe to the Global Hemophilia Report Connect with the Global Hemophilia Report Global Hemophilia Report on LinkedIn Global Hemophilia Report on Twitter Global Hemophilia Report on Facebook Connect with BloodStream Media: BloodStreamMedia.com BloodStream on Facebook BloodStream on Twitter
Yes, for exactly the right reasons, researchers in the US safely created a relatively lethal form of the coronavirus inside a lab. And also, yes — scientists did answer the question of whether a goat or a sheep would win in a fight. (NOTE: No animals were harmed for that study.)
Yes, we're still 'springing forward' and 'falling back' every year. But when it comes to human health, one of those time changes is way different than the other.
What could an AI creative tool like DALL-E 2 or Midjourney look like in the next few years? This video explores the full set of future possibilities upon us! GPT-X, Diffusion, and our Multimodal Future (Part II) BOOK: https://docs.google.com/document/d/1TeRMqOsGX8kiK_mNiCt4yxO26Yjk6BdM/ Timestamps: 00:00 - Intro 05:02 - Multimodal Model Characteristics 11:26 - Creating a new image 15:56 - Prompt writing capabilities - Prompt Formatting 16:50 - Prompt autocompletion, intelligent suggestions 19:57 - Built in prompt unbundling 21:57 - Configure Recombinants 23:45 - Recombinant blending modes 25:07 - Configure Recombinant Unbundling Details 26:12 - Recombinant Layers & Node based 28:05 - Recombinant Import Bench 29:48 - Natural Language Image editing - refresh individual objects 31:44 - Edit mode - Natural Langauge Edit Prompts 32:37 - Edit prompt realtime feedback 33:05 - Natural language hex color editing support 34:35 - Advanced Natural Language Edit Prompt Changes 35:53 - Edit prompt intensity (UI controls) 36:59 - Multimodal Object Transformations 37:16 - Lighting & Camera Controls 38:00 - Advanced Editing Tools (Fix AI Weirdness and more) 39:27 - Edit images via markup (markup prompt) 40:43 - Logical Variations 43:57 - Realtime Collaboration 44:28 - Recombinant Collaborators 46:06 - Built in Music Player 48:45 - Creative Hyperparameters 49:20 - Text Capabilities - Magic Text 50:52 - Text Capabilities - Magic Text Fill 52:41 - Latent Variation Scrubbing 53:34 - Explore Alternatives 56:34 - Productivity and commercialization 58:06 - Analysis & Feedback 59:16 - Advanced Multimodal Capabilities 1:03:45 - Offline Capabilities 1:11:11 - Advanced Workflow Support 1:11:58 - Closing thoughts GPT-X, DALL-E, and our Multimodal Future (Part I): https://www.youtube.com/playlist?list=PLza3gaByGSXjUCtIuv2x9fwkx3K_3CDmw Links: DALL-E 2 Unbundling https://bakztfuture.substack.com/p/dall-e-2-unbundling DALL-E 2: Recombinant Art & Design https://bakztfuture.substack.com/p/dall-e-2-recombinant-art-and-design DALL-E 2 - Unofficial Natural Language Image Editing, Art Critique Survey https://bakztfuture.substack.com/p/dall-e-2-unofficial-natural-language-b14 Please note I do not represent, have any affiliation with, nor do I speak on behalf of OpenAI. Subscribe to the Multimodal Podcast! Spotify - https://open.spotify.com/show/7qrWSE7ZxFXYe8uoH8NIFV Apple Podcasts - https://podcasts.apple.com/us/podcast/multimodal-by-bakz-t-future/id1564576820 Google Podcasts - https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkLnBvZGJlYW4uY29tL2Jha3p0ZnV0dXJlL2ZlZWQueG1s Stitcher - https://www.stitcher.com/show/multimodal-by-bakz-t-future Other Podcast Apps (RSS Link) - https://feed.podbean.com/bakztfuture/feed.xml Connect with me: YouTube - https://www.youtube.com/bakztfuture Substack Newsletter - https://bakztfuture.substack.com Twitter - https://www.twitter.com/bakztfuture Instagram - https://www.instagram.com/bakztfuture Github - https://www.github.com/bakztfuture
September 2022 - State of the Union Slideshow presentation! Watch the video of this presentation here: https://www.youtube.com/watch?v=qYvRsLWpMBs Links from this episode: GPT-X, DALL-E, and our Multimodal Future: https://www.youtube.com/playlist?list=PLza3gaByGSXjUCtIuv2x9fwkx3K_3CDmw InstructGPT: https://openai.com/blog/instruction-following/ InstructGPT vs. google search: https://bakztfuture.substack.com/p/instructgpt-google-search WebGPT: https://openai.com/blog/webgpt/ Recombinant art: https://bakztfuture.substack.com/p/dall-e-2-recombinant-art-and-design DALL-E 2: Emerging Content Category Breakdown: https://bakztfuture.substack.com/p/dall-e-2-emerging-content-category DALL-E 2 - Unofficial Natural Language Image Editing, Art Critique Survey https://bakztfuture.substack.com/p/dall-e-2-unofficial-natural-language-b14 My Biggest 2022 Prediction: GPT-3 will take over schools and college campuses https://bakztfuture.substack.com/p/my-biggest-2022-prediction-gpt-3 Subscribe to the Multimodal Podcast! Spotify - https://open.spotify.com/show/7qrWSE7ZxFXYe8uoH8NIFV Apple Podcasts - https://podcasts.apple.com/us/podcast/multimodal-by-bakz-t-future/id1564576820 Google Podcasts - https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkLnBvZGJlYW4uY29tL2Jha3p0ZnV0dXJlL2ZlZWQueG1s Stitcher - https://www.stitcher.com/show/multimodal-by-bakz-t-future Other Podcast Apps (RSS Link) - https://feed.podbean.com/bakztfuture/feed.xml Connect with me: YouTube - https://www.youtube.com/bakztfuture Substack Newsletter - https://bakztfuture.substack.com Twitter - https://www.twitter.com/bakztfuture Instagram - https://www.instagram.com/bakztfuture Github - https://www.github.com/bakztfuture
In this episode, we review the high-yield topic of Recombinant Cytokines from the Immunology section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbulletsIn --- Send in a voice message: https://anchor.fm/medbulletsstep1/message
This episode is sponsored by BTG Speciality Pharmaceuticals. BTG provides rescue medicines typically used in emergency rooms and intensive care units to treat patients for whom there are limited treatment options. They are dedicated to delivering quality medicines that make a real difference to patients and their families through the development, manufacture, and commercialization of pharmaceutical products. Their current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with some heart and cancer medications. --- Dr. Canter is a Surgical Oncologist with clinical expertise in the multidisciplinary management of sarcomas. He also runs a translational research laboratory which focuses on the therapeutic and mechanistic effects of combining natural killer (NK) cell immunotherapy with other treatment modalities to overcome NK dysfunction in the tumor microenvironment of solid tumors, including sarcomas in both humans and dogs. He serves as the co-leader of UC Davis Comprehensive Cancer Center's Comparative Oncology Program, and his laboratory is one of a select group of labs internationally which is studying canine NK cells, including first-in-dog studies of canine immunotherapy and adoptive transfer of NK cells in dogs with osteosarcoma. Dr. Rebhun is a an Associate Professor in the Department of Surgical and Radiological Sciences at the Center for Companion Animal Health at the UC Davis School of Veterinary Medicine. His research focus is in the field of comparative and translational oncology, with specific interests in metastasis and novel therapeutics. --- What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨ EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter.
Recombinant vaccines are not a silver bullet, but they are “very helpful for our goals in the poultry industry, whether you produce meat-type chickens or commercial table eggs,” said Guillermo Zavala, DVM, PhD, with Avian Health International. To maximize their effectiveness, Zavala said producers need to follow a number of protocols when using recombinant vaccines.Chapters:0:00 Intro0:11 Guillermo Zavala, DVM, PhD, Poultry Consultant 0:30 Recombinant vector vaccination mistakes2:07 Dosing recombinant vector vaccines3:33 Recombinant vector vaccine administration4:27 In ovo vaccination5:43 Ensuring better bird health6:51 Recombinant vector vaccine advantages________________________________________________Poultry Health Today is a news publication sponsored by Zoetis designed to bring broiler, layer and turkey producers the latest news and insights on poultry health, welfare, performance and sustainability. Visit us at PoultryHealthToday.com and follow us on LinkedIn, Facebook and Twitter. For more on our sponsor, visit Zoetis.com.
Yuning Chen discusses The “ProVir™” collection and the role of recombinant virus proteins in the development of infectious disease treatment regimes and vaccines.
Herpes zoster is a public health concern for the public, especially in subjects who are immunocompromised. The CDC–recommended recombinant zoster vaccine (RZV) is an effective way to reduce the incidence of herpes zoster, but because of the increased immunogenicity of the vaccine adjuvant, there is a concern about flares of underlying autoimmune diseases in rheumatology patients. Join Drs. Syed Raza Saurav Acharya, and Gabrielle Howard, as they discuss the safety of RZV in this patient population, a topic they, and their coauthor Debendra Pattanaik, addressed in their February 2022 Southern Medical Journal article. In this podcast, they talk about why patients with rheumatic diseases are found to be at higher risk of herpes zoster and what led them to conduct their study. Additionally, they provide evidence of the safety of RZV in subjects with rheumatologic diseases.
In this episode, we discuss recombinant proteins: what are they and what are they used for? BioTechniques Editor Tristan Free speaks to Amy Sheng, Technical Account Manager at Sino Biological, who explains the history of recombinant proteins and how protein modeling techniques such as AlphaFold are changing their development. Find out how monoclonal antibodies have been used through the COVID-19 pandemic and how we may overcome challenges in production, upscaling and more in this episode of Talking Techniques. Contents:Introduction 00:00-01:26What are recombinant proteins and what are they used for? 01:26 – 02:42How were they first developed? 02:42 – 03:50Since initial development has recombinant antibody development progressed today? 03:50 – 05:57What are the advantages of utilizing the more traditional mouse monoclonal antibodies? 05:57 – 07:11Are recombinant antibodies used in more specialist applications and are they more likely to be used in therapeutics? 07:11 – 09:47How have AI systems like AlphaFold impacted the development of recombinant antibodies? 09:47 – 12:07How has antibody production changed and what's next? 12:07 – End
In this episode, we discuss recombinant proteins: what are they and what are they used for? BioTechniques Editor Tristan Free speaks to Amy Sheng, Technical Account Manager at Sino Biological, who explains the history of recombinant proteins and how protein modeling techniques such as AlphaFold are changing their development. Find out how monoclonal antibodies have been used through the COVID-19 pandemic and how we may overcome challenges in production, upscaling and more in this episode of Talking Techniques. Contents:Introduction 00:00-01:26What are recombinant proteins and what are they used for? 01:26 – 02:42How were they first developed? 02:42 – 03:50Since initial development has recombinant antibody development progressed today? 03:50 – 05:57What are the advantages of utilizing the more traditional mouse monoclonal antibodies? 05:57 – 07:11Are recombinant antibodies used in more specialist applications and are they more likely to be used in therapeutics? 07:11 – 09:47How have AI systems like AlphaFold impacted the development of recombinant antibodies? 09:47 – 12:07How has antibody production changed and what's next? 12:07 – End See acast.com/privacy for privacy and opt-out information.
In the USA, the big news is Ketanji Jackson is on US SCOTUS.
Recombinant Activated Human Factor VII. John Ingram, CCP is your host.
Frank Schaeffer In Conversation with Emmy-nominated composer McKenzie Stubbert, exploring the traditions of film music, 20th Century Minimalism, and his forthcoming album, Waiting Room._____LINKSmckenziestubbert.comInstagramTwitterElletroRespirEverybody Goes to the Hospital Teaser_____McKenzie Stubbert is an Emmy-nominated composer based in Los Angeles. His work is steeped in the traditions of film music, electronic art-music, and the minimalists of the late 20th Century. Collaborators include Katherine Bigelow, Pharrell Williams, Alex Gibney, Black Francis, and Tim Fain. His work has shown at international film and music festivals including Cannes, Sundance, Toronto, Tribeca, and Sonar+D.Receiving a formal music education from the University of Oregon, he initially pursued a freelance career scoring ads for brands like NETFLIX, NIKE, and LAIKA.In 2014, he began a multi-year collaboration with immersive artist Chris Milk, scoring VR experiences. EVOLUTION OF VERSE (Annapurna Pictures) premiered at Sundance 2015, eventually showing all over the world, including President Barack Obama. In 2016, The New York Times' THE DISPLACED, won the Cannes Lions Grand Prix and he live-scored Milk's TED Talk, The Birth of VR. In 2017, he was invited to speak at the Sonar+D festival in Barcelona and scored the Emmy-nominated documentary ELIÁN for Jigsaw Productions and CNN Films.In 2018, with writer James Nestor and Allison Pelissier he created the light inducement cinematic experience AETERNA, which premiered at Grey Area's RECOMBINANT 2020 in San Francisco.From 2019-2021, he was part of the musical project ELLETRO with cellist Caleigh Drane, creating modern classical works only using a single instrument and studio techniques from contemporary electronic music production, releasing two acclaimed EPs.In early 2021, he completed his first solo album entitled, WAITING ROOM._____In Conversation… with Frank Schaeffer is a production of the George Bailey Morality in Public Life Fellowship. It is hosted by Frank Schaeffer, author of Fall In Love, Have Children, Stay Put, Save the Planet, Be Happy.Learn more at https://www.lovechildrenplanet.comFollow Frank on Facebook, Twitter, and YouTube.https://www.facebook.com/frank.schaeffer.16https://twitter.com/Frank_Schaefferhttps://www.youtube.com/c/FrankSchaefferYouTubeIn Conversation… with Frank Schaeffer PodcastApple Podcasts: https://podcasts.apple.com/us/podcast/in-conversation-with-frank-schaeffer/id1570357787Spotify: https://open.spotify.com/show/1FVF48mNwzNaLd1tJ4zH6y?si=aeVQ54ieTA-hlSuMNB5APA&dl_branch=1_____Support the show
Not all coronavirus variants are equal. And this one may not even exist.
FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)
Listen to a soundcast of the July 1, 2021 FDA approval of Rylaze (asparaginase erwinia chrysanthemi (recombinant) - rywn) for treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma in patients who have developed hypersensitivity to E. coli-derived asparaginase.
My AP Biology Thoughts Unit 5 HeredityWelcome to My AP Biology Thoughts podcast, my name is Victoria Villagran and I am your host for episode #101 called Unit 5 Heredity: Linked Genes. Today we will be discussing linked genes and their characteristics! Segment 1: Introduction to Linked Genes Linked Genes A form of non-mendelian inheritance Discovered by Thomas Hunt Morgan, using the fruit fly Drosophila melanogaster Genes on the same chromosome, making them more likely to be inherited together If crossing over occurs, then they are no longer linked it will look like independent assortment If they are linked, they will not assort independently and the ratios of the offspring will different If there are more parental phenotypes, then it is linked If there are more recombinant then is it non-linked The recombination frequency is very small. If the genes are far apart on a chromosome, or on different chromosomes, the recombination frequency is 50%. ... If the recombination frequency is less than 50% we say the two loci are linked Recombinant and Map Units: The farther apart the genes are on the chromosome, the more likely they are to separate because of crossing over resulting in recombinant offspring Recombinant offspring generally appear in proportions related to the recombination frequency between the two genes: Calculated by dividing the number of recombinant progeny by the total number of progeny This can be used to calculate map units or how far away the genes are from each other Segment 2: More About Linked Genes Let's look at fruit flies If linkage held true, then F1 would only have the two parental phenotypes in a 1:1 ratio The genes for eye color and the genes for wing length are on the same chromosome, thus are inherited together. A cross between gray and normal with black vestigial There are more parental phenotypes with 965 and 944 than recombinant with 206 for gray and vestigial, and 185 with black normal. There is an expected 575 frequency for each genotype they are linked, so they did not assort independently and the ratios of actual offspring were different from the expected Segment 3: Connection to Heredity Linked genes and heredity, specific non-mendelian inheritance are connected Heredity or inheritance is the passing on of traits or genetic information from one generation to the the next, and linked genes are a specific way how these genes are passed on from being on the same chromosome and not independently assorted, giving more parental phenotypes. For example, the farther apart the genes are on the chromosome, the more likely they are to separate because of crossing over resulting in recombinant offspring. The location and space between genes dictate the way they will be inherited by new generations. Thank you for listening to this episode of My AP Biology Thoughts. For more student-ran podcasts and digital content, make sure that you visit http://www.hvspn.com (www.hvspn.com). Have a nice day! Music Credits: "Ice Flow" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/by/4.0/ Subscribe to our Podcast https://podcasts.apple.com/us/podcast/my-ap-biology-thoughts/id1549942575 (Apple Podcasts) https://open.spotify.com/show/1nH8Ft9c9f6dmo75V9imCk (Spotify) https://podcasts.google.com/search/my%20ap%20biology%20thoughts (Google Podcasts ) https://www.youtube.com/channel/UC07e_nBHLyc_nyvjF6z-DVg (YouTube) Connect with us on Social Media Twitterhttps://twitter.com/thehvspn ( @thehvspn)
Qu'est-ce qu'un recombinant ? Merci d'avoir posé la question ! Dans la famille des coronavirus mutants, on commence à bien connaître les variants : britannique, brésilien, sud-africain… Maintenant, voici-venu les recombinants ! Des genres d'hybridations entre différents variants, qui ont été repérés au Royaume-Uni. Au Royaume-Uni, le consortium COG-UK séquence et analyse le génome des coronavirus qui circulent sur le territoire. Cette institution créée au début de la pandémie de Covid19 a annoncé le 17 mars 2021 avoir observé une quinzaine de “recombinants” : des coronavirus de type Sars-Cov-2, dont le code génétique mélange des morceaux du variant britannique et des morceaux de souches anciennes. Leurs observations laissent penser que ces recombinants ont été transmis d'une personne à une autre. Comment ça s'explique que des virus se mélangent comme ça ? Doit-on s'inquiéter des recombinants ? Quelle est la solution pour lutter contre ? Ecoutez la suite dans cet épisode de "Maintenant vous savez". Un podcast écrit et réalisé par Quentin Tenaud. A écouter aussi : Qu'est-ce que le VOC2020 ? Qu'est-ce que la stratégie vaccinale ? Qu'est-ce que le passeport sanitaire ? Vous pouvez réagir à cet épisode sur notre page Twitter. Voir Acast.com/privacy pour les informations sur la vie privée et l'opt-out. Learn more about your ad choices. Visit megaphone.fm/adchoices
Dr Ciaccio (not a doctor) looks into new science breakthroughs including the discovery of a newly discovered recombinant coronavirus strain that has pieces of two different strains. Plus the unearthing of a 5000 year old Egyptian Brewery that could get feed 9000 people a day. A new study in which researchers have communicated with lucid dreamers in real time, and another unexpected discovery of life in an extremely uncomfortable place (Antarctica).
In the fourth and final part of our review of the year we talk about Woolly Rhinos, Chang'e 5 and Panto Dames. Recombinant vector vaccines, Edward Snowden and Dread Pirate Roberts. Plus we chuck in a quick review of the Egyptian dynastic period and life (or not) on Venus.What's not to like!Support the show (https://www.patreon.com/TDMF)
This episode covers recombinant cytokines and their clinical uses!
Verrex has been sold to a VC firm. Starting a new company with the same management team. D&B has joined the AVnu Alliance. Converging mass notification and entertainment systems. Host: Tim Albright Guests: Lindsey Adler, Ernie Beck, and Joe Cornwall Runtime: 35:20 Click to Watch the Video: Subscribe to AVWeek: Links to Sources: Verrex bought [...]
Verrex has been sold to a VC firm. Starting a new company with the same management team. D&B has joined the AVnu Alliance. Converging mass notification and entertainment systems. Host: Tim Albright Guests: Lindsey Adler, Ernie Beck, and Joe Cornwall Runtime: 35:20 Click to Watch the Video: Subscribe to AVWeek: Links to Sources: Verrex bought [...]
© 2020-2025 Ivy Podcast Discovery LLC
